- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Lenvatinib is a multi-target tyrosine kinase inhibitor mainly used to treat malignant tumors such as thyroid cancer, hepatocellular carcinoma, ...
Lenvatinib is a multi-target tyrosine kinase inhibitor mainly used for the treatment of malignant tumors such as thyroid cancer, hepatocellular...
Lenvatinib is an oral multi-target tyrosine kinase inhibitor developed by Eisai Corporation in Japan. It is mainly used to treat malignant tumo...
Lenvatinib is an oral multi-target tyrosine kinase inhibitor developed by Eisai Corporation in Japan. It is mainly used to treat malignant tumo...
The standard dose of Ponatinib is 45mg orally once daily, and the specific number of tablets to be taken needs to be calculated according to th...
The treatment cycle of Ponatinib needs to be personalized according to the type of disease, treatment response, and tolerance. It is usually co...
Ponatinib, as a third-generation BCR-ABL tyrosine kinase inhibitor, has significant therapeutic effects on chronic myeloid leukemia (CML) and ...
Whether Ponatinib needs to be taken for a long time depends on the type of disease, treatment response, and individual tolerance. It is usually...
Tucatinib usually requires long-term use, and the specific medication cycle depends on the disease progression and patient tolerance. It genera...
As a HER2 targeted drug, Tucatinib has shown significant efficacy in the treatment of breast cancer and colorectal cancer, especially in patien...
